Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination with Multiple Agents in Subjects with Advanced Solid Tumors
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs HCB-101 (Primary) ; Bevacizumab; Capecitabine; Cetuximab; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pembrolizumab; Pertuzumab; Ramucirumab; Toripalimab; Trastuzumab
- Indications Colorectal cancer; Gastric cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors FBD Biologics
- 20 Jan 2025 New trial record